| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/27/2004 | WO2004043415A1 Stimulation of hair growth by compositions containing peptide copper complexes and minoxidil |
| 05/27/2004 | WO2004043406A2 ENGINEERED RNAi ADENOVIRUS SILENCING EXPRESSION (ERASE) OF DNA REPAIR PROTEINS |
| 05/27/2004 | WO2004043404A2 Process for designing inhibitors of influenza virus non-structural protein 1 |
| 05/27/2004 | WO2004043403A2 Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use |
| 05/27/2004 | WO2004043397A2 Compositions and methods for the treatment of rheumatoid arthritis |
| 05/27/2004 | WO2004043394A2 Modulation of huntingtin interacting protein 1 expression |
| 05/27/2004 | WO2004043391A2 Modulation of mitogen-activated protein kinase kinase kinase 11 expression |
| 05/27/2004 | WO2004043385A2 Methods and compositions for prostate epithelial cell differentiation |
| 05/27/2004 | WO2004043383A2 A new target for angiogenesis and anti-angiogenesis therapy |
| 05/27/2004 | WO2004043381A2 Compositions and methods for prolonging survival of platelets |
| 05/27/2004 | WO2004043374A2 Methods and compositions for treating cancer using proteasome inhibitors |
| 05/27/2004 | WO2004043373A2 Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme |
| 05/27/2004 | WO2004043361A2 Compositions and methods for the treatment of natural killer cell related diseases |
| 05/27/2004 | WO2004043357A2 Method of making, and the use of cytotoxic agents containing elemental selenium |
| 05/27/2004 | WO2004043356A2 Coated dibasic calcium phosphate |
| 05/27/2004 | WO2004043348A2 Histone deacetylase inhibitors for treating degenerative diseases of the eye |
| 05/27/2004 | WO2004043340A2 Alpha 5 beta 1 and its ability to regulate the cell survival pathway |
| 05/27/2004 | WO2004043339A2 Substituted cycloalkyl p1' hepatitis c virus inhibitors |
| 05/27/2004 | WO2004043336A2 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
| 05/27/2004 | WO2004043332A2 Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases |
| 05/27/2004 | WO2004043287A2 Novel compositions that enhance production performance in avians |
| 05/27/2004 | WO2004043232A2 Methods for identifying risk of melanoma and treatments thereof |
| 05/27/2004 | WO2004043141A2 Novel inhibin-related multiple antigenic peptide compositions that enhance production performance in avians |
| 05/27/2004 | WO2004030628A9 Adult bone marrow derived stem cells |
| 05/27/2004 | WO2004028521A3 Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders |
| 05/27/2004 | WO2004016653A8 Bactericidal, anti-apoptotic, pro-inflammatory and anti-inflammatory peptides of heparin-binding protein (hbp) or human neutrophil elastase |
| 05/27/2004 | WO2004012775A3 Bicistronic vector encoding a vegf and an fgf, use thereof |
| 05/27/2004 | WO2003105784A8 Compositions and methods for softening, thinning and removing hyperkeratotic tissue |
| 05/27/2004 | WO2003099992A3 Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins |
| 05/27/2004 | WO2003095637B1 Combination of a growth factor and a protease enzyme |
| 05/27/2004 | WO2003086278A8 Intrapleural single-chain urokinase alone or complexed to its soluble receptor protects against pleural adhesions |
| 05/27/2004 | WO2003082926A9 Antimicrobial polymer conjugates |
| 05/27/2004 | WO2003081258A3 Diagnostics and therapeutics for diseases associated with growth hormone secretagogue receptor (ghs) |
| 05/27/2004 | WO2003072749A3 Enkurin and uses thereof |
| 05/27/2004 | WO2003070888B1 Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid |
| 05/27/2004 | WO2003068977A3 Fusion constructs containing active sections of tnf ligands |
| 05/27/2004 | WO2003064448A3 Degp protease: cleavage site identification and proteolysis of a natural target in e. coli |
| 05/27/2004 | WO2003061589A3 Methods for treating diseases or conditions with peptide constructs |
| 05/27/2004 | WO2003059276B1 Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof |
| 05/27/2004 | WO2003054550A3 Uses of an endothelial cell receptor |
| 05/27/2004 | WO2003033658A3 Neutrokine-alpha and neutrokine-alpha splice variant |
| 05/27/2004 | WO2003028659A3 Methods and compositions for modulating apoptosis |
| 05/27/2004 | WO2003018748A3 Anti-cancer and wound healing compounds |
| 05/27/2004 | WO2003015705A3 In situ immunization |
| 05/27/2004 | WO2003014155A3 Labelled conjugates of p17 protein and their use in aids diagnosis |
| 05/27/2004 | WO2003004604A3 Phage displayed pdz domain ligands |
| 05/27/2004 | WO2003001249A3 Modulating photoreactivity in a cell |
| 05/27/2004 | WO2002102854A3 Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| 05/27/2004 | WO2002097037A8 Melanin-concentrating hormone analogs |
| 05/27/2004 | WO2002095062A3 Serine-threonine phosphatase protein of a parasitic organism of the apicomplexa phylum, applications in therapeutics |
| 05/27/2004 | WO2002092827A3 Corona-virus-like particles comprising functionally deleted genomes |
| 05/27/2004 | WO2002085923A3 In vivo incorporation of unnatural amino acids |
| 05/27/2004 | WO2002085406A9 Methods and compositions for treating conditions associated with insulin resistance |
| 05/27/2004 | WO2002081413A3 One dimensional unichemo protection (ucp) in organic synthesis |
| 05/27/2004 | WO2002079393A3 Dynamic action reference tools |
| 05/27/2004 | WO2002060480A9 Methods for treating or preventing skin disorders using cd2-binding agents |
| 05/27/2004 | WO2002058673A8 Method of preparing pharmaceutical or dietary compositions for conveying labile substances into the intestine |
| 05/27/2004 | WO2000073764A3 Composition and methods for the therapeutic use of an atonal-associated sequence |
| 05/27/2004 | WO1999046281A8 Novel polypeptides and nucleic acids encoding the same |
| 05/27/2004 | WO1999042077A3 Compositions and methods for regulating lymphocyte activation |
| 05/27/2004 | US20040103448 Using rodent animal model to monitor effectivenes of cell proliferation, viabilty and differentiation inhibitors |
| 05/27/2004 | US20040102624 Compositions and methods for regulating autolytic processes in bacteria |
| 05/27/2004 | US20040102623 Modulation of PAK1 expression |
| 05/27/2004 | US20040102622 Modulation of hepatocyte growth factor receptor expression |
| 05/27/2004 | US20040102621 Modulation of forkhead box C2 expression |
| 05/27/2004 | US20040102615 Method for isolating and purifying a protein and resulting protein |
| 05/27/2004 | US20040102613 For prophylactic/therapeutic drugs for heart/central nervous system diseases; diagnostic kits |
| 05/27/2004 | US20040102611 For treatment of human diseases; drug screening; bllt analysis; genetic engineering; kits |
| 05/27/2004 | US20040102609 Peptide-containing alpha-ketoamide cysteine and serine protease inhibitors |
| 05/27/2004 | US20040102607 Trimeric antigenic O-linked glycopeptide conjugates, methods of preparation and uses thereof |
| 05/27/2004 | US20040102605 For prevention/treatment of Pseudomonas infections |
| 05/27/2004 | US20040102496 Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
| 05/27/2004 | US20040102478 Alzheimer's and Parkinson's disease; antiinflamamtory agents; antiallergens; vision defects |
| 05/27/2004 | US20040102448 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade |
| 05/27/2004 | US20040102422 Administering human papillomaviruse protein; urogenital cancer therapy |
| 05/27/2004 | US20040102415 Diffusion of aqueous brine solution containing antioxidant and arginine; fluid flow circuits |
| 05/27/2004 | US20040102413 Method and reagent for the inhibition of telomerase enzyme |
| 05/27/2004 | US20040102412 Antisense modulation of GFAT expression |
| 05/27/2004 | US20040102410 In particular, invention relates to alphavirus-based, preferably Sindbis virus-based, vectors and to non-alphavirus-based vectors, which have a preferential affinity for high affinity laminin receptors |
| 05/27/2004 | US20040102409 Medicament for locally treating or preventing a chemotherapy-induced mucositis and other side effects resulting from chemotherapy |
| 05/27/2004 | US20040102408 Method and medicament for inhibiting the expression of a given gene |
| 05/27/2004 | US20040102407 Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer |
| 05/27/2004 | US20040102406 Phosphorothioate oligonucleotides directed to a subunit of an integrin vitronectin receptor to inhibit angiogenesis and/or metastasis |
| 05/27/2004 | US20040102405 Using compounds comprising oligonucleotides targeted to nucleic acid encoding squalene synthase; for diagnosis and treatment of disease associated with expression of squalene synthase; cardiovascular disorders, atherosclerosis |
| 05/27/2004 | US20040102403 Using compounds comprising oligonucleotides targeted to fibrillarin; for diagnosis and treatment of disease associated with expression of fibrillarin; proliferative disorders, cancer |
| 05/27/2004 | US20040102402 Using compounds comprising oligonucleotides targeted to nucleic acid encoding tissue factor; for diagnosis and treatment of disease associated with expression of tissue factor; cardiovascular disorders, cancer |
| 05/27/2004 | US20040102401 Using compounds comprising oligonucleotides targeted to nucleic acid encoding jagged 1; for diagnosis and treatment of disease associated with expression of jagged 1; developmental disorders, cancer |
| 05/27/2004 | US20040102400 Using compounds comprising oligonucleotides targeted to nucleic acid encoding UBE2G1; for diagnosis and treatment of disease associated with expression of UBE2G1; autoimmune, developmental, neurodegenerative disorders, cancer |
| 05/27/2004 | US20040102399 Using compounds comprising oligonucleotides targeted to nucleic acid encoding hypothetical protein 669; for diagnosis and treatment of disease associated with expression of hypothetical protein 669; metabolic disorders |
| 05/27/2004 | US20040102398 Using compounds comprising oligonucleotides targeted to nucleic acid encoding B7H; for diagnosis and treatment of disease associated with expression of B7H; autoimmune diseases |
| 05/27/2004 | US20040102397 Modulation of PPM1B expression |
| 05/27/2004 | US20040102396 Modulation of BCL2-associated athanogene 5 expression |
| 05/27/2004 | US20040102391 Using compounds, especially nucleic acid and nucleic acid-like oligomers, which are targeted to a nucleic acid encoding Gankyrin, and which modulate the expression of Gankyrin |
| 05/27/2004 | US20040102390 Modulation of Notch3 expression |
| 05/27/2004 | US20040102389 Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
| 05/27/2004 | US20040102388 Modified blood clotting factors and methods of use |
| 05/27/2004 | US20040102384 Pyrrolidine derivatives and their use as chymase inhibitor |
| 05/27/2004 | US20040102381 Methods of altering the binding affinity of a peptide to its receptor |
| 05/27/2004 | US20040102379 Fibroblast growth factor homologous factors (FHFs) and methods of use |
| 05/27/2004 | US20040102378 Peptides as solubilizing excipients for transforming growth factor beta proteins |